A liposarcoma is a rare cancer that develops in fat cells. It accounts for roughly 1 in 100,000 people diagnosed each year, making it one of the more common types of soft tissue sarcoma while still being uncommon overall. These tumors can grow anywhere in the body where fat tissue exists, but they most frequently appear in the thigh, the deep abdomen behind the organs (called the retroperitoneum), and the trunk.
Where Liposarcomas Develop
The extremities account for about 52% of all cases, with the thigh alone representing 60% of those. The retroperitoneum is the second most common site at 19%, followed by the trunk (18%) and the head and neck region (9%). Because fat tissue is found throughout the body, liposarcomas can technically appear almost anywhere, but these four areas account for the vast majority of diagnoses.
The location matters because it shapes how the tumor behaves, how quickly it’s noticed, and what treatment options are available. A mass growing in the thigh is far easier to detect early than one buried deep in the abdomen, where it can grow for months or years before causing noticeable problems.
The Five Subtypes
Not all liposarcomas are the same. The World Health Organization recognizes five distinct subtypes, and the differences between them are significant enough to affect treatment decisions and long-term outlook.
Well-differentiated liposarcoma is the most common and least aggressive subtype. These tumors grow slowly and closely resemble normal fat cells under a microscope. The five-year survival rate is approximately 82%. In the extremities, this subtype is sometimes called an “atypical lipoma” because of its low-grade behavior, though it can still recur locally after removal.
Dedifferentiated liposarcoma starts as or develops from a well-differentiated tumor but contains areas of higher-grade, more aggressive cells. It shares the same genetic signature as well-differentiated liposarcoma but carries a greater risk of spreading to distant sites.
Myxoid liposarcoma has a distinctive appearance under the microscope, with a rich network of small blood vessels set against a gel-like background. This subtype tends to respond better to chemotherapy and radiation than other forms.
Pleomorphic liposarcoma is the most aggressive subtype. It grows rapidly, is more likely to spread to the lungs and other organs, and has a five-year survival rate of about 51%.
Myxoid pleomorphic liposarcoma is exceedingly rare and unusual because it primarily affects children and adolescents, with a higher occurrence in girls. It combines features of both the myxoid and pleomorphic subtypes and behaves aggressively, with high recurrence rates and early spread to the lungs, bones, and soft tissues.
What Drives the Cancer at a Genetic Level
The most common liposarcoma subtypes, well-differentiated and dedifferentiated, share a specific genetic fingerprint. These tumors carry extra copies of a region on chromosome 12 that contains two key genes. One of these genes produces a protein that disables p53, one of the body’s most important tumor-suppressing mechanisms. Normally, p53 acts as a checkpoint that stops damaged cells from multiplying. When this gene is amplified, p53 gets broken down faster than it should, removing that safety brake.
The second gene drives cells through a critical growth checkpoint, pushing them from a resting state into active division. Together, these two genetic changes both disable a major cancer defense and accelerate cell growth. Studies consistently find these amplifications in over 90% of well-differentiated and dedifferentiated tumors, which is why testing for them has become a standard part of diagnosis.
Symptoms by Location
Most liposarcomas cause no symptoms in their early stages. Many are discovered by accident during imaging ordered for something else entirely. Symptoms typically appear only once the tumor has grown large enough to press on surrounding structures.
Extremity Tumors
The most common presentation is a painless, slowly growing lump. Pain develops in 30% to 40% of cases, usually a dull ache caused by the mass compressing nearby nerves or blood vessels. About 15% to 20% of patients experience tingling, numbness, or weakness when nerves are involved. In the legs, large tumors can compress veins and cause swelling, visible surface veins, or skin changes. Tumors that exceed 20 centimeters can restrict joint movement or cause one limb to look noticeably larger than the other.
Retroperitoneal Tumors
These are harder to catch early. The most common complaints, reported in 50% to 60% of patients, are a feeling of fullness in the abdomen and getting full quickly when eating. Dull, constant abdominal pain occurs in 40% to 50% of cases. Because the tumor grows slowly in a spacious area, it can reach a significant size before anyone notices. Progressive abdominal swelling and unexplained weight gain are sometimes mistaken for normal aging or weight changes. Fatigue, appetite loss, and unintentional weight loss occur in 20% to 30% of patients with larger or more aggressive tumors. As the mass grows, it can press on the kidneys (causing flank pain or blood in the urine), the bowel (causing constipation), or major blood vessels (causing leg swelling).
Trunk, Head, and Neck
Tumors in the chest wall, back, or abdominal wall usually show up as a lump you can feel with localized swelling. Those growing inside the chest cavity can cause shortness of breath, coughing, or chest pain. In the head and neck, symptoms depend on the exact site: tumors in the mouth can make swallowing or speaking difficult, laryngeal tumors cause hoarseness, and neck masses may compress the airway or esophagus.
How It’s Told Apart From a Lipoma
Most fatty lumps are lipomas, which are completely benign and extremely common. On MRI, a simple lipoma appears as a uniformly fatty mass with, at most, a few thin internal walls (septa) less than 2 millimeters thick. When a fatty mass meets those criteria, MRI is 100% specific for a benign lipoma.
Features that raise suspicion for liposarcoma include thickened or lumpy septa (generally over 2 millimeters), non-fatty solid areas within the mass, bright spots on certain MRI sequences, and areas that light up with contrast dye. Any of these findings typically prompt a biopsy. Size also matters practically: fatty masses larger than 5 centimeters, deep-seated masses, and masses that are growing warrant closer evaluation.
Who Gets Liposarcoma
Liposarcoma incidence peaks between the ages of 75 and 84. Men are affected roughly twice as often as women, with peak rates around 5 per 100,000 in men compared to about 2 per 100,000 in women within that age group. Population studies show the overall incidence has been increasing over recent decades, though some of that rise likely reflects improved detection through more widespread use of advanced imaging. No clear environmental or lifestyle risk factor has been established for most cases.
Treatment Approach
Surgery is the primary treatment. The goal is to remove the tumor completely with a margin of healthy tissue around it to reduce the chance of recurrence. For low-grade tumors, a margin as small as 2 millimeters may be sufficient. High-grade tumors generally require wider margins, typically more than 2 centimeters, though the exact distance depends on the anatomy and whether natural barriers like muscle lining or bone covering sit at the edge of the resection.
For tumors in the arms or legs, preserving the limb while still achieving complete removal is a central priority. Surgeons work to maintain critical nerves, blood vessels, and functional muscle, which sometimes means the margin of tissue removed is narrower in certain directions. When that’s the case, radiation therapy is used to compensate.
Radiation can be given either before or after surgery. Both approaches reduce the risk of the cancer returning locally, but they carry different trade-offs. Pre-operative radiation uses a lower total dose (50 Gy versus 66 Gy) and treats a smaller area, which means fewer long-term side effects like joint stiffness, chronic swelling, and tissue scarring. However, it comes with a higher rate of wound healing complications after surgery, especially for lower leg tumors. Post-operative radiation avoids wound issues but delivers a higher dose over a larger field, increasing the risk of those longer-term complications. Studies suggest pre-operative radiation provides slightly better local control.
For myxoid liposarcoma specifically, chemotherapy plays a more meaningful role than in other subtypes. Standard first-line chemotherapy produces response rates around 40%. A second option, trabectedin, achieves response rates around 20% by traditional measurement but often performs better when assessed by alternative criteria that capture tumor changes more sensitively. This makes it a viable option for patients who cannot tolerate standard chemotherapy or whose disease returns after initial treatment.
Long-Term Outlook
Prognosis varies dramatically by subtype. Well-differentiated liposarcoma has a five-year survival rate of about 82%, reflecting its slow growth and low tendency to spread. Pleomorphic liposarcoma, at the other end of the spectrum, has a five-year survival rate near 51%. The other subtypes fall somewhere in between.
Beyond subtype, several factors influence outcomes. Tumor location plays a role: retroperitoneal liposarcomas are harder to remove completely and tend to recur locally more often than extremity tumors. Tumor size at diagnosis, depth, and whether the surgical margins are clear of cancer cells all affect recurrence risk. Well-differentiated tumors can recur locally, sometimes repeatedly over many years, without ever spreading to distant organs. Dedifferentiated and pleomorphic subtypes carry a real risk of metastasis, most commonly to the lungs. Long-term follow-up with periodic imaging is standard for all subtypes, often extending 10 years or more given the potential for late recurrence.